MA52004A - Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase - Google Patents
Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidaseInfo
- Publication number
- MA52004A MA52004A MA052004A MA52004A MA52004A MA 52004 A MA52004 A MA 52004A MA 052004 A MA052004 A MA 052004A MA 52004 A MA52004 A MA 52004A MA 52004 A MA52004 A MA 52004A
- Authority
- MA
- Morocco
- Prior art keywords
- glycopyranosidase
- acetamido
- deoxy
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642932P | 2018-03-14 | 2018-03-14 | |
| US201862690536P | 2018-06-27 | 2018-06-27 | |
| US201862699443P | 2018-07-17 | 2018-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52004A true MA52004A (fr) | 2021-01-20 |
Family
ID=65952097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052004A MA52004A (fr) | 2018-03-14 | 2019-03-13 | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230117898A1 (fr) |
| EP (2) | EP3765458B1 (fr) |
| JP (1) | JP7453916B2 (fr) |
| CN (2) | CN118955490A (fr) |
| AU (1) | AU2019234759C1 (fr) |
| CA (1) | CA3093315A1 (fr) |
| ES (1) | ES2942211T3 (fr) |
| MA (1) | MA52004A (fr) |
| MX (1) | MX2020009530A (fr) |
| WO (1) | WO2019178191A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045745A1 (fr) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga |
| KR20210060513A (ko) | 2018-09-19 | 2021-05-26 | 바이오젠 엠에이 인코포레이티드 | O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제 |
| WO2021094312A1 (fr) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga contenant de la pyrrolidine et de la bicyclohétéroaryle |
| WO2021110656A1 (fr) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga |
| BR112022011812A2 (pt) | 2019-12-18 | 2022-08-30 | Janssen Pharmaceutica Nv | Compostos inibidores da oga |
| KR20220118483A (ko) | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | Oga 억제제 화합물 |
| WO2021123291A1 (fr) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Composés inhibiteurs d'oga |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| CN114213315A (zh) * | 2021-12-31 | 2022-03-22 | 上海陶术生物科技有限公司 | 含氮杂环类化合物及其中间体的合成方法 |
| CN114560805B (zh) * | 2022-01-20 | 2024-11-29 | 上海陶术生物科技有限公司 | 含氮杂环化合物及其中间体的合成方法 |
| CN121405694A (zh) * | 2024-07-26 | 2026-01-27 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013075084A1 (fr) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| WO2013078320A1 (fr) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| WO2013120104A2 (fr) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
| EP2953941B1 (fr) | 2013-02-11 | 2017-04-05 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| SI2970272T1 (sl) | 2013-03-14 | 2019-06-28 | Merck Patent Gmbh | Inhibitorji glikozidaze |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3033334A1 (fr) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées |
| US10913733B2 (en) * | 2015-12-18 | 2021-02-09 | Alectos Therapeutics Inc. | Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof |
| CA3044762A1 (fr) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Composes inhibiteurs d'oga bicyclique |
| JP2020503298A (ja) | 2016-12-16 | 2020-01-30 | ヤンセン ファーマシューティカ エヌ．ベー． | 単環式ｏｇａ阻害剤化合物 |
| CA3045745A1 (fr) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga |
-
2019
- 2019-03-13 CN CN202410813893.5A patent/CN118955490A/zh active Pending
- 2019-03-13 EP EP19713945.4A patent/EP3765458B1/fr active Active
- 2019-03-13 JP JP2020548963A patent/JP7453916B2/ja active Active
- 2019-03-13 CN CN201980019170.5A patent/CN112218863B/zh active Active
- 2019-03-13 AU AU2019234759A patent/AU2019234759C1/en active Active
- 2019-03-13 EP EP23151036.3A patent/EP4186899A1/fr active Pending
- 2019-03-13 WO PCT/US2019/021995 patent/WO2019178191A1/fr not_active Ceased
- 2019-03-13 MX MX2020009530A patent/MX2020009530A/es unknown
- 2019-03-13 MA MA052004A patent/MA52004A/fr unknown
- 2019-03-13 CA CA3093315A patent/CA3093315A1/fr active Pending
- 2019-03-13 ES ES19713945T patent/ES2942211T3/es active Active
-
2022
- 2022-08-24 US US17/894,461 patent/US20230117898A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020009530A (es) | 2021-01-15 |
| ES2942211T3 (es) | 2023-05-30 |
| AU2019234759B2 (en) | 2024-08-01 |
| CN112218863B (zh) | 2024-07-12 |
| JP2021518340A (ja) | 2021-08-02 |
| US20230117898A1 (en) | 2023-04-20 |
| AU2019234759A1 (en) | 2020-09-17 |
| CN118955490A (zh) | 2024-11-15 |
| CN112218863A (zh) | 2021-01-12 |
| CA3093315A1 (fr) | 2019-09-19 |
| AU2019234759C1 (en) | 2025-02-06 |
| EP3765458A1 (fr) | 2021-01-20 |
| WO2019178191A1 (fr) | 2019-09-19 |
| EP4186899A1 (fr) | 2023-05-31 |
| JP7453916B2 (ja) | 2024-03-21 |
| EP3765458B1 (fr) | 2023-01-11 |
| WO2019178191A8 (fr) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| EP3843714C0 (fr) | Inhibiteurs de cd73 | |
| EP4007756C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| EP3787635A4 (fr) | Inhibiteurs de cd73 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3980011C0 (fr) | Inhibiteurs de sarm1 | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA50906A (fr) | Inhibiteurs d'immunoprotéasome |